Northwell Health partnered with Stacker to analyze federal resources and news articles to illustrate how health crisis ...

Neurosurgeon and scientist Dr. Jandial joined us to discuss a major breakthrough in pain medication recently approved by the ...

The change in leadership comes shortly after Indivior warned that it is expecting a sharp decline in its revenues in 2025, ...

Spark Biomedical, Inc. is a leading U.S.-based medical device developer, committed to unlocking the potential of bioelectronic medicine and bringing to market novel wearable neurostimulation treatment ...

SB161 would require that non-opioid pain treatments that have FDA approval be included on this preferred drug list with coverage terms that are no more restrictive than those given to opioid pain ...

Health care providers can now administer Sublocade subcutaneously into the thigh, buttock, or the back of the upper arm, in addition to the abdomen.

The FDA has approved label changes for once-monthly Sublocade, helping to reduce possible barriers to treatment initiation ...

In looking at the profound impact on satiety that GLP-1s have, Penn State College of Medicine Drs. Patrician Grigson and ...

Indivior said the U.S. Food and Drug Administration approved label changes for its opioid-dependence treatment Sublocade, including a rapid initiation protocol and alternative injection sites.

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...

It’s time for Pennsylvania to update its standing health orders to allow for the use of all FDA-approved opioid overdose ...